HOGA1 Suppresses Renal Cell Carcinoma Growth via Inhibiting the Wnt/β‐Catenin Signalling Pathway
Journal of Cellular and Molecular Medicine · 2025-03 · 29 (6)
DOI: 10.1111/jcmm.70490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 18.03.2025. Verfasst von Congmin Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Binzhou Medical University, Yantai, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Wnt Signaling Pathway, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, Youth Science Foundation project of Shandong Province Natural Science Foundation, Key R&D Program of Shandong Province.
Abstract (Originalsprache)
Changes in hydroxyproline metabolism are reported to promote tumorigenesis. HOGA1 is a useful marker for diagnosing primary hyperoxaluria 3, catalysing the final step of mitochondrial hydroxyproline metabolism from 4‐hydroxy‐2‐oxoglutarate (HOG) to glyoxylate and pyruvate; however, its specific mechanism in RCC remains unclear. This study investigated the role of HOGA1 in the pathogenesis of ccRCC. The results showed that HOGA1 was decreased significantly in tumour tissues, with this low expression associated with a poor prognosis in patients with ccRCC. QTL mapping showed that Hoga1 was cis ‐regulated. Gene enrichment analyses showed that Hoga1 co‐expressed genes were enriched in the Wnt/β‐catenin signalling pathway. Furthermore, in vitro and in vivo assays demonstrated that HOGA1 significantly inhibited the proliferation, invasion and migration of renal carcinoma cells via the Wnt/β‐catenin–c‐Myc/CyclinD1 axis, probably via regulating the level of HOG. In conclusion, this study demonstrates that HOGA1 has a tumour suppressor role by inhibiting the Wnt/β‐catenin signalling pathway. This finding provides new insights into the function of HOGA1 in ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Binzhou Medical University, Yantai, China.
- Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, China.
- The Second School of Clinical Medicine, Binzhou Medical University, Yantai, China.
- The First School of Clinical Medicine, Binzhou Medical University, Yantai, China.
ORCID-Profile: Cuifang Yao
Förderung
- The National Natural Science Foundation of China
- Youth Science Foundation project of Shandong Province Natural Science Foundation
- Key R&D Program of Shandong Province
- Binzhou Medical University
- Taishan Scholars Construction Engineering Projects
Zitieren
APA
Wang, C., Liu, Y., Tan, Y., Xu, F., Wang, M., Tang, Y., Nie, G., Chi, X., Xu, Z., Xu, Y., An, B., Tian, G., Qi, D., & Yao, C. (2025). HOGA1 Suppresses Renal Cell Carcinoma Growth via Inhibiting the Wnt/β‐Catenin Signalling Pathway. Journal of Cellular and Molecular Medicine, 29(6). https://doi.org/10.1111/jcmm.70490
Vancouver
Wang C, Liu Y, Tan Y, Xu F, Wang M, Tang Y, et al. HOGA1 Suppresses Renal Cell Carcinoma Growth via Inhibiting the Wnt/β‐Catenin Signalling Pathway. Journal of Cellular and Molecular Medicine. 2025;29(6). doi:10.1111/jcmm.70490
BibTeX
@article{Wang2025,
author = {Wang, Congmin and Liu, Yu and Tan, Ying and Xu, Fuyi and Wang, Mingyao and Tang, Yiming and Nie, Guofeng and Chi, Xiaodong and Xu, Zhaowei and Xu, Yuxue and An, Baijiao and Tian, Geng and Qi, Donglai and Yao, Cuifang},
title = {HOGA1 Suppresses Renal Cell Carcinoma Growth via Inhibiting the Wnt/β‐Catenin Signalling Pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
volume = {29},
number = {6},
doi = {10.1111/jcmm.70490}
}
EUVIMED